Padlock Therapeutics

Padlock Therapeutics is developing medicines targeting protein-arginine deiminases (PADs), enzymes with an important role in the generation of autoantigens, inflammation, and immune complexes in autoimmune diseases. Padlock intends to explore the full biological and therapeutic footprint of protein deimination by PADs. Padlock is based in Cambridge, MA.

Latest News Entry
2016/01/04
Padlock Therapeutics Creates West Coast Operations Appointing Scientific Co-founder Kerri Mowen, Ph.D., as Director of Biology Based in San Diego

Padlock Therapeutics, a biotechnology company dedicated to creating new medicines for destructive autoimmune diseases, today announced the appointment of Kerri Mowen, Ph.D., one of

all portfolio news